IMO it’s self evident that CPAP works. Resmed have built a circa $50 billion business around this widget. Mechanical ventilation is effective but it’s not suitable for everyone, and it doesn’t address the underlying condition.
The exciting part for IHL shareholders is there are no competing drugs in this space. If IHL-42X becomes a genuine treatment in the space then it’s going to be worth billions. Even a modest 10% penetration of Resmed’s market would represent a material market cap for IHL.
GW Pharma had a US$3 billion market cap on Epidiolex pre revenue and they were targeting orphaned conditions of epilepsy. OSA is a much more significant market and its growing an estimated 6% per annum. That’s a golden opportunity.
- Forums
- ASX - By Stock
- IHL
- General discussion
General discussion, page-11992
-
-
- There are more pages in this discussion • 7,905 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IHL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online